A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)

被引：0
|
作者：
Glitza, I. C. [1 ]
Rohlfs, M. L. [1 ]
Iqbal, M. [1 ]
Richard, J. [1 ]
Burton, E. [1 ]
Duncan, S. [1 ]
Brown, C. [1 ]
Anderson, J. [1 ]
Hwu, P. [1 ]
Hwu, W-J. [1 ]
Wong, M. [1 ]
Yee, C. [1 ]
Patel, S. [1 ]
Woodman, S. [1 ]
Amaria, R. [1 ]
Diab, A. [1 ]
Tawbi, H. [1 ]
Davies, M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1301TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)
    Long, G. V.
    Atkinson, V. G.
    Lo, S.
    Sandhu, S. K.
    Brown, M.
    Gonzalez, M.
    Guminski, A.
    Scolyer, R. A.
    Emmett, L.
    Menzies, A. M.
    McArthur, G. A.
    ANNALS OF ONCOLOGY, 2019, 30 : 534 - 534
  • [42] CA045-001: A phase Ill, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
    Khushalani, Nikhil I.
    Diab, Adi
    Ascierto, Paolo Antonio
    Larkin, James M. G.
    Sandhu, Shahneen Kaur
    Sznol, Mario
    Koon, Henry B.
    Jarkowski, Anthony
    Zhou, Ming
    Wang, Rui
    Bajaj, Gaurav
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
    Long, Georgina V.
    Atkinson, Victoria
    Lo, Serigne
    Guminski, Alexander David
    Sandhu, Shahneen Kaur
    Brown, Michael Paul
    Gonzalez, Maria
    Scolyer, Richard A.
    Emmett, Louise
    McArthur, Grant A.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
    Gettinger, S.
    Beck, T.
    Yang, X.
    Telivala, B.
    Morgensztern, D.
    Velcheti, V.
    Ramalingam, S. S.
    Schalper, K.
    Dajee, M.
    Ranck, A.
    Yang, R.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
    Kiyohara, Y.
    Takenouchi, T.
    Uhara, H.
    Koga, H.
    Uchi, H.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Phase 2 study of nivolumab (NIVO) in Japanese patients with previously untreated advanced melanoma: long-term efficacy and safety
    Yamazaki, N.
    Uhara, H.
    Kiyohara, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Phase I study of the nivolumab combined with IFN-B in patients with advanced melanoma
    Fujimura, T.
    Kambayashi, Y.
    Furudate, S.
    Hidaka, T.
    Aiba, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S48 - S48
  • [48] Treatment beyond progression with nivolumab (nivo in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.
    Escudier, Bernardi.
    Motzer, Roberti.
    Sharma, Padmanee
    Wagstaff, John
    Plimack, Elizabeth R.
    Hammers, Hans J.
    Donskov, Frede
    Gurney, Howard
    Sosman, Jeffrey Alan
    Zalewski, Pawel
    Harmenberg, Ulrika
    McDermott, David F.
    Choueiri, Toni K.
    Richardet, Martin Eduardo
    Tomita, Yoshihiko
    Ravaud, Alain
    Doan, Justin
    Zhao, Huanyu
    Hardy, Helene
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study
    EI-Khoueiry, Anthony B.
    Sangro, Bruno
    Yau, Thomas Cheung
    Crocenzi, Todd S.
    Welling, Theodore Hobart
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    Dela Cruz, Christine Marie
    Lang, Lixin
    Neely, Jaclyn
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.
    Fenton, Sarah Elizabeth
    Kircher, Sheetal Mehta
    Mulcahy, Mary Frances
    Mahalingam, Devalingam
    Salem, Riad
    Lewandowski, Robert
    Kulik, Laura
    Benson, Al Bowen
    Kalyan, Aparna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345